Fresenius Medical Care AG & Co. KGaA Announces Management Board Changesvor 1 Minute veröffentlicht
Fresenius Medical Care AG & Co. KGaA Announces Management Board Changes
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Schlagwort(e):
Fresenius Medical Care AG & Co. KGaA Announces Management Board
12.03.2014 / 17:57
March 12, 2014
Fresenius Medical Care Announces Management Board Changes
Bad Homburg, Germany- Fresenius Medical Care AG&Co. KGaA ( the "company" or
Fresenius Medical Care, " Frankfurt Stock Exchange: FME/ New York Stock
Exchange:FMS), the world's largest provider of dialysis products and
services, today announced two changes in the Management Board.
Prof. Emanuele Gatti (58), the Management Board member currently
responsible for the region Europe, Middle East, Africa and Latin America
(EMEALA) and Global Chief Strategist, has decided as a personal choice to
enter the next phase of his career. Prof. Gatti will discontinue his
operational responsibilities and Management Board position effective March
31, 2014 and in his new role as Executive Advisor for Healthcare Strategies
and Policies, he will support CEO Rice Powell in selecting strategic
opportunities as well as represent the company in several external
committees. In addition, and in combination with his academic activities,
he will continue to work for the company to develop regenerative medicine
and to improve dialysis and blood purification therapies.
Prof. Emanuele Gatti began his career with Fresenius dialysis business
segment in January 1989 and after several successful years with increasing
responsibilities, including managing the Southern European dialysis
business, he was appointed to the Management Board of Fresenius Medical
Care AG in May 1997. "This change had been planned, and now, for personal
reasons, it seems the right time to move into the next phase of my life.
Over all these years, working to develop life-saving products and services
together with wonderful employees, I have been able to contribute to the
global growth and success of this special company. This has always been a
source of great pleasure for me. With the planned future projects, I am
sure that I will further contribute to the improvement of renal care for
thousands of patients," Emanuele Gatti said.
Effective April 1, 2014, Mr. Dominik Wehner will succeed Prof. Gatti as the
Management Board Member for the Europe, Middle East and Africa region while
the Latin America region under John Anderson's management will report to
Dominik Wehner (45) began his career at Fresenius Medical Care in 1994 as
Sales Manager and is currently Executive Vice President responsible for the
regions of Eastern Europe, Middle East and Africa which he turned into one
of the growth drivers of EMEALA. He also serves on the Vifor Fresenius
Medical Care Renal Pharma Board of Directors and was instrumental in the
successful extension of the venture activities in EMEALA.
Dr. Rainer Runte (54), the Management Board member currently responsible
for Global Law, Compliance, Intellectual Property and Labor relations in
Germany, has informed the company he does not intend to renew his contract,
which concludes December 31, 2014. Dr. Runte and the company mutually
agreed he will step down from the Management Board and his daily
responsibilities on April 1, 2014. Until such time a permanent successor to
Dr. Runte is named, David Kembel, Chief Compliance Officer for Fresenius
Medical Care North America, will assume responsibility for Global
Compliance on an interim basis. Rice Powell as the Chairman of the
Management Board will assume Dr. Runte's remaining responsibilities until
the search for a General Counsel is complete. Dr. Runte will remain
connected to Fresenius Medical Care through his advisory role on matters of
corporate law and compliance.
Dr. Runte began his career with Fresenius in 1990, became Senior Vice
President for Law at Fresenius Medical Care in 1997 and was appointed to
the Management Board in 2002. Before joining the company, he worked as a
university research assistant and as an attorney in a law firm specializing
in economic law. "After 24 years of contributions to the success of
Fresenius Medical Care and being a Management Board Member for 13 years, I
believe the time has come for me to take some time away from the day-to-day
work activities and decide which career direction I might want to pursue,"
Rainer Runte said.
Ulf Mark Schneider, Chairman of the Supervisory Board of Fresenius Medical
Care Management AG, commented: "Emanuele Gatti and Rainer Runte have made
significant contributions to Fresenius Medical Care. Both were instrumental
in building the company into the global dialysis leader it is today. I
respect their decisions and appreciate that the company will continue to
benefit from their experience and insights as part of their advisory roles.
On behalf of the Supervisory Board, I would like to thank them for their
dedication, perseverance and outstanding results. At the same time, I would
like to welcome Dominik Wehner to his new role on Fresenius Medical Care's
Management Board. Dominik is a proven executive with significant dialysis
products and service experience and an impressive track record. I am
convinced that the Europe, Middle East and Africa region will continue to
thrive under his inspiring and energetic leadership."
Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2.5 million
individuals worldwide. Through its network of 3,250 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatments for 270,122 patients around the
globe. Fresenius Medical Care is also the world's leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
For more information about Fresenius Medical Care, visit the company's
website at www.fmc-ag.com.
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
Ende der Corporate News
12.03.2014 Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch die DGAP - ein Unternehmen der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,
Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap-medientreff.de und
Unternehmen: Fresenius Medical Care AG & Co. KGaA
61352 Bad Homburg
Telefon: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Börsen: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart; Terminbörse EUREX; NYSE
Ende der Mitteilung DGAP News-Service